Seegene (096530) Fundamentals 2026 — P/E 23.0x, Revenue Analysis | SniperIQ
Seegene (096530) is a KR-listed Healthcare company in Medical - Specialties with a market capitalization of ₩1.23T, trading at ₩26900.00 on the KOE. This SniperIQ fundamentals page covers Seegene's valuation (P/E 23.0x, P/B 1.4x), profitability (net margin 11.1%), revenue (₩474.2B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Seegene's market cap?
Seegene (096530) has a market capitalization of approximately ₩1.23T, trading at ₩26900.00 on the KOE. Market cap moves with the live share price.
What is Seegene's P/E ratio?
Seegene's trailing twelve-month P/E ratio is 23.0x, with a price-to-book (P/B) of 1.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Seegene?
Seegene runs a net profit margin of 11.1%, a gross margin of 60.8%, and an operating margin of 9.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Seegene generate?
Seegene reported revenue of ₩474.2B for fiscal year 2025, with net income of ₩48.4B and earnings per share (EPS) of 1047. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Seegene pay a dividend?
Seegene offers a trailing dividend yield of about 4.0%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Seegene financially healthy?
Seegene carries a debt-to-equity ratio of 0.13x and a current ratio of 4.46x, with a market beta of 0.90. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Seegene a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Seegene (096530) the key facts are: market cap ₩1.23T, P/E 23.0x, revenue ₩474.2B, 52-week range 21700-32500. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Seegene's full fundamentals live
Get Seegene's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.